Actinium Pharmaceuticals (ATNM) Financial Statements & Analysis

Actinium Pharmaceuticals (ATNM) Income Statement

Actinium Pharmaceuticals reported revenue of $90.00K in fiscal 2025 (fiscal year ended Dec 31, 2025). Actinium Pharmaceuticals posted a net loss of $33.89M, compared with a net loss of $38.24M a year earlier. Gross margin was 100.0% and operating margin -40274.4%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $35.00M.

Actinium Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Actinium Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	0.09	0.00	0.08	1.03	1.03	1.14	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.81	0.00	0.00	-	0.52	0.45	0.42	0.05	0.06
Gross Profit	0.09	-0.81	0.08	1.03	1.03	0.62	-0.45	-0.42	-0.05	-0.06
Operating Expenses
Research & Development	21.12	30.05	38.67	23.14	23.14	17.51	16.09	16.55	17.10	17.70
Selling, General & Administrative	15.21	12.08	13.33	12.00	12.00	8.08	6.31	5.10	6.73	9.16
Operating Expenses	36.34	42.12	52.00	35.13	35.13	25.58	22.39	21.65	23.83	26.91
Operating Income	-36.25	-42.12	-51.92	-34.10	-34.10	-24.96	-22.39	-22.07	-23.83	-26.91
Other Income/Expense
Interest Income	2.36	3.88	3.10	1.09	1.09	0.19	0.18	0.17	0.17	0.01
Interest Expense	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.17	0.01
Other Income/Expense	2.36	3.88	3.10	1.09	1.09	0.19	0.18	0.17	0.17	0.31
Income
Income Before Tax	-33.89	-38.24	-48.82	-33.02	-33.02	-24.77	-22.22	-21.90	-23.65	-26.60
Income Tax Expense	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.17	0.00
Net Income	-33.89	-38.24	-48.82	-33.02	-33.02	-24.77	-22.22	-21.90	-23.65	-26.60
Net Income - Continuous Operations	-33.89	-38.24	-48.82	-33.02	-33.02	-24.77	-22.22	-21.90	-23.65	-26.60
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	-36.06	-41.31	-51.71	-32.32	-33.41	-24.25	-22.26	-21.48	-23.78	-26.86
EBIT	-36.25	-42.12	-51.92	-	-34.10	-24.96	-22.39	-	-	-
Depreciation & Amortization	0.82	0.81	0.21	0.70	0.70	0.52	0.14	0.42	0.05	0.06
Earnings Per Share
Basic EPS	-1.00	-1.00	-2.00	-1.00	-1.00	-1.00	-2.00	-4.00	-7.00	-12.00
Diluted EPS	-1.00	-1.00	-2.00	-1.00	-1.00	-1.00	-2.00	-4.00	-7.00	-12.00
Basic Shares Outstanding	31.20	30.07	26.60	24.14	24.14	20.57	12.13	4.98	3.54	2.23
Diluted Shares Outstanding	31.20	30.07	26.60	24.14	24.14	20.57	12.13	4.98	3.54	2.23

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Actinium Pharmaceuticals Financial Statements

What was Actinium Pharmaceuticals's revenue in fiscal 2025?

Actinium Pharmaceuticals reported revenue of $90.00K in fiscal 2025 (fiscal year ended Dec 31, 2025).

Is Actinium Pharmaceuticals profitable?

No. Actinium Pharmaceuticals reported a net loss of $33.89M in fiscal 2025. In fiscal 2024 it lost $38.24M.

What is Actinium Pharmaceuticals's operating margin?

Actinium Pharmaceuticals's operating income was −$36.25M on revenue of $90.00K in fiscal 2025, an operating margin of -40274.4%.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition